Wall Street brokerages expect Endo International PLC (NASDAQ:ENDP) to report earnings of $0.73 per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Endo International PLC’s earnings, with the lowest EPS estimate coming in at $0.65 and the highest estimate coming in at $0.81. Endo International PLC posted earnings of $0.86 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 15.1%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Tuesday, August 8th.

On average, analysts expect that Endo International PLC will report full-year earnings of $3.61 per share for the current financial year, with EPS estimates ranging from $3.45 to $3.73. For the next financial year, analysts forecast that the company will report earnings of $3.46 per share, with EPS estimates ranging from $3.02 to $3.80. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Endo International PLC.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.13. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.08 EPS.

Several brokerages have issued reports on ENDP. Guggenheim began coverage on Endo International PLC in a research report on Saturday, June 17th. They issued a “hold” rating and a $12.00 target price on the stock. Deutsche Bank AG dropped their target price on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th. Royal Bank Of Canada set a $15.00 price objective on Endo International PLC and gave the company a “hold” rating in a research report on Saturday, April 8th. Zacks Investment Research cut Endo International PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Canaccord Genuity set a $12.00 price objective on Endo International PLC and gave the company a “hold” rating in a research report on Thursday, June 8th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $17.33.

Shares of Endo International PLC (NASDAQ ENDP) traded down 1.87% during trading on Tuesday, hitting $12.06. 3,229,153 shares of the company were exchanged. Endo International PLC has a 1-year low of $9.70 and a 1-year high of $24.93. The company has a 50 day moving average of $11.78 and a 200-day moving average of $12.04. The stock’s market capitalization is $2.69 billion.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/07/18/analysts-anticipate-endo-international-plc-endp-will-announce-earnings-of-0-73-per-share.html.

Several large investors have recently modified their holdings of ENDP. Amalgamated Bank raised its position in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock valued at $361,000 after buying an additional 619 shares in the last quarter. Meeder Asset Management Inc. raised its position in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock valued at $544,000 after buying an additional 677 shares in the last quarter. Capstone Asset Management Co. raised its position in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock valued at $358,000 after buying an additional 960 shares in the last quarter. Point View Wealth Management Inc. raised its position in shares of Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares in the last quarter. Finally, Jensen Investment Management Inc. raised its position in shares of Endo International PLC by 5.8% in the first quarter. Jensen Investment Management Inc. now owns 24,660 shares of the company’s stock valued at $275,000 after buying an additional 1,360 shares in the last quarter. Institutional investors and hedge funds own 93.17% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International PLC (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.